Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision oncology. Among the highlights is the MONSTAR-SCREEN-3 study, which demonstrates the power of Myriad Genetics, Inc. (NASDAQ:MYGN)’s whole-genome sequencing-based Precise MRD test to detect circulating tumor DNA (ctDNA) […]